# About Zephyr AI

### AI for Real-World Precision—Turning Data Into Patient Impact

Zephyr AI is redefining precision medicine with AI-enabled software and enterprise-scale real-world data. By transforming fragmented clinical and biological information into actionable insights, we advance therapeutic development, patient stratification, and diagnostic innovation—bringing clarity to complexity and impact to patients.

**Our Mission**

To transform precision medicine with AI-enabled software that integrates seamlessly into existing workflows for rapid validation and clinical translation. Alongside our models, we provide access to one of the world’s largest multimodal clinicogenomic datasets—enabling partners to explore populations, accelerate discovery, and improve trial success.

**Our Vision**

A future where precision medicine is accessible, immediate, and effective—where treatment decisions for every patient are guided by robust, biologically grounded insights tailored to each patient’s unique disease biology. By designing AI that imbues rich biological context into routine clinical inputs and delivers clinically actionable outputs, Zephyr creates tools that lay the foundation for more effective, personalized treatment while expanding access to precision medicine.

### Core Principles Underlying Our AI

Zephyr’s AI is built on three principles: learn from a lot, refine with a little, and enrich limited patient data with deep biological context. By interpreting even sparse inputs against this foundation, we uncover hidden insights that transform today’s limited clinical data into powerful precision medicine software.

### Our Team

We are scientists, engineers, clinicians, business leaders, and innovators united by a shared mission to make precision medicine more effective and accessible through technology. At the intersection of machine learning and real-world data, we bring clarity where it matters most.

We move fast, collaborate deeply, and value diverse perspectives. Together, we are redefining precision medicine—with scalable software, real-world intelligence, and a team built to deliver for patients and partners alike.

**Leadership** 
- **Allen Chao, Ph.D.   Chief Executive Officer**  
    
  A lifelong champion for cancer patients and research—and a cancer survivor himself—Dr. Allen Chao is deeply committed to advancing precision medicine.

- **Jeff Sherman, MSCS   Co-Founder, Chief Technology Officer**  
    
  Jeff Sherman is Co-Founder and Chief Technology Officer at Zephyr AI, where he leads the architecture of secure, scalable AI and data platforms that help partners match therapies to patients and bring precision medicine to scale.

- **Anshu Jain, MD   Chief Business and Clinical Officer**  
    
  Dr. Anshu Jain is Zephyr AI’s Chief Business and Clinical Officer. A double board-certified radiation oncologist and clinical informatician, he leads business development, clinical strategy, medical affairs, and partner collaborations.

- **John Applegate, MBA   Chief Financial Officer**  
    
  John Applegate is the Chief Financial Officer of Zephyr AI with over 25 years of experience in finance and strategy in biotechnology.

- **Justin Stebbing, MD   Chairman, Scientific + Medical Advisory Board**  
    
  Dr. Justin Stebbing is the Chairman of Zephyr AI’s Scientific and Medical Advisory Board, specializing in solid malignancies and author of over 700 papers.

- **Franziska Michor, PhD   Founding Advisor**  
    
  Dr. Fanziska Michor is a Professor of Computational Biology, investigating evolutionary dynamics of cancer.

### Interested in learning more about our custom AI solutions?

#### We’d love to hear from you.